GlaxoSmithKline Pharmaceuticals Complete Financial Statements
In FY2026, GlaxoSmithKline Pharmaceuticals (GLAXO) reported revenue ₹1,031 Cr, net profit ₹278 Cr and EPS ₹16.40, with a net profit margin of 27.0% and ROE of 12.3%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see GlaxoSmithKline Pharmaceutical share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GLAXO Revenue, Net Profit & EBITDA — Year-on-Year Growth
GLAXO YoY (Mar 2025 vs Mar 2026) — revenue +1.6%, net profit +5.7%, EBITDA +3.5%, expenses +0.5%. Explore GLAXO investment value to estimate fundamental worth using multiple valuation models.
GLAXO Income Statement — Revenue, EBITDA & Net Profit
GlaxoSmithKline Pharmaceuticals revenue ₹1,031 Cr, EBITDA ₹387 Cr, net profit ₹278 Cr, EPS ₹16.40 (2026) — net profit margin 27.0%. Review GLAXO PE ratio trends to evaluate earnings-based valuation against sector peers.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,031 | 1,016 | 1,015 | 849 | 1,091 | 1,050 | 962 | 850 | 985 | 985 | 826 | 815 | 833 | 939 | 2,132 | 776 | 826 | 964 | 785 | 764 | 838 | 888 | 803 | 707 | 834 | 1,299 | 823 | 819 | 795 | 831 | 754 | 871 |
| Expenses | 644 | 644 | 641 | 554 | 670 | 689 | 673 | 584 | 658 | 668 | 618 | 618 | 751 | 660 | 634 | 596 | 585 | 678 | 707 | 586 | 636 | 739 | 602 | 535 | 611 | 688 | 588 | 623 | 1,408 | 663 | 608 | 688 |
| EBITDA | 387 | 372 | 374 | 295 | 421 | 361 | 290 | 266 | 327 | 318 | 208 | 198 | 83 | 279 | 1,497 | 180 | 241 | 286 | 78 | 178 | 202 | 150 | 201 | 172 | 223 | 611 | 236 | 196 | -613 | 168 | 145 | 183 |
| Operating Profit Margin % | 35.00% | 34.00% | 34.00% | 31.00% | 36.00% | 32.00% | 28.00% | 28.00% | 31.00% | 30.00% | 22.00% | 19.00% | 7.00% | 28.00% | 22.00% | 20.00% | 27.00% | 27.00% | 5.00% | 18.00% | 22.00% | 16.00% | 22.00% | 18.00% | 23.00% | 22.00% | 22.00% | 21.00% | -81.00% | 19.00% | 17.00% | 17.00% |
| Depreciation | 13 | 17 | 15 | 16 | 20 | 17 | 18 | 16 | 19 | 18 | 17 | 16 | 17 | 16 | 15 | 16 | 16 | 17 | 18 | 18 | 18 | 22 | 23 | 22 | 18 | 23 | 14 | 19 | 18 | 12 | 11 | 12 |
| Interest | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 3 | 0 | 0 | 0 |
| Profit Before Tax | 373 | 354 | 359 | 279 | 400 | 344 | 271 | 249 | 308 | 299 | 190 | 181 | 65 | 262 | 1,482 | 163 | 224 | 268 | 60 | 160 | 184 | 127 | 177 | 149 | 204 | 587 | 222 | 176 | -634 | 157 | 134 | 171 |
| Tax | 95 | 97 | 96 | 74 | 104 | 91 | 76 | 67 | 78 | 82 | 57 | 49 | 20 | 69 | 263 | 44 | 60 | 64 | 45 | 39 | 34 | 51 | 39 | 38 | 48 | 85 | 75 | 63 | 27 | 56 | 50 | 57 |
| Net Profit | 278 | 258 | 263 | 205 | 296 | 253 | 195 | 182 | 230 | 218 | 133 | 132 | 46 | 193 | 1,219 | 119 | 165 | 204 | 14 | 121 | 150 | 77 | 138 | 111 | 157 | 503 | 147 | 114 | -661 | 101 | 84 | 114 |
| Earnings Per Share (₹) | 16.40 | 15.07 | 15.52 | 12.10 | 16.54 | 14.67 | 11.37 | 10.76 | 13.57 | 12.84 | 7.41 | 7.04 | 9.89 | 11.42 | 71.96 | 7.04 | 9.71 | 12.06 | 0.85 | 7.14 | 8.87 | 4.51 | 8.15 | 6.54 | 10.26 | 29.68 | 8.67 | 6.70 | -39.03 | 5.95 | 9.93 | 6.71 |
GLAXO Balance Sheet — Assets, Liabilities & Shareholders' Equity
GLAXO total assets ₹4,324 Cr, total equity ₹2,267 Cr, total liabilities ₹ Cr (2026) — ROE 12.3%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 4,324 | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 | 3,216 |
| Current Assets | 3,606 | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 | 2,174 | 2,587 |
| Fixed Assets | 314 | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 | 210 | 123 |
| Capital Work in Progress | 33 | 14 | 14 | 20 | 31 | 13 | 120 | 1,003 | 923 | 606 | 268 | 115 |
| Investments | 458 | 1,118 | 813 | 518 | 366 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 2,692 | 2,408 | 2,458 | 3,907 | 2,715 | 2,257 | 2,477 | 2,700 | 2,140 | 2,577 | 2,977 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 277 | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 | 292 | 280 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 2,267 | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 | 2,183 | 1,829 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 | 85 | 85 |
| Reserves & Surplus | 2,098 | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 | 2,099 | 1,744 |
GLAXO Cash Flow Statement — Operating, Investing & Financing
GlaxoSmithKline Pharmaceuticals operating cash flow ₹1,290 Cr, investing ₹-46 Cr, financing ₹-769 Cr, net cash flow ₹475 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 | 139 | 338 |
| Investing Activities | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 | 499 | 180 |
| Financing Activities | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 | -638 | -497 |
| Net Cash Flow | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 | 0 | 21 |